Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis-Reference-Cited by-同舟云学术

Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis

Published:2005-02 Issue:1 Volume:16 Page:15-18
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Hon K. L. E.,Leung T. F.,Ma K. C.,Wong Y.,Fok T. F.

Publisher

Informa UK Limited

Subject

Dermatology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference20 articles.

1. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis.

2. Hypothalamic-Pituitary-Adrenal Function and Glucocorticoid Sensitivity in Atopic Dermatitis

3. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis

4. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: A pilot study

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review on the off-label use of montelukast in atopic dermatitis treatment;International Journal of Clinical Pharmacy;2018-05-18

2. Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all;Journal of Clinical Pharmacy and Therapeutics;2017-11-07

3. Cysteinyl leukotriene E 4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D 2 and epithelial cytokines;Journal of Allergy and Clinical Immunology;2017-10

4. A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children;Allergy, Asthma & Immunology Research;2016

5. MSCs and Asthma;Stem Cell Biology and Regenerative Medicine;2016